Advancing Next-Generation T-Type Calcium Channel Medicines for Essential Tremor and Movement Disorders
Mission
Acurex Biosciences is developing differentiated, brain-penetrant small-molecule medicines for movement disorders and neurodegenerative diseases. Our most advanced program, CU-00048, is a next-generation T-type calcium channel modulator being advanced for Essential Tremor, a common and disabling movement disorder with limited treatment options.
Approach
Recent clinical progress in Essential Tremor has validated T-type calcium channel modulation as one of the most important new therapeutic opportunities in movement disorders. Praxis Precision Medicines has made a major contribution to the field by establishing clinical and regulatory validation for this mechanism. Acurex is building on this progress with CU-00048, a differentiated T-type modulator designed to address the continuing need for improved tolerability, dose flexibility, and long-term usability.
validation
CU-00048 is supported by preclinical efficacy in tremor-relevant models, differentiated state-dependent T-type pharmacology, favorable drug-like properties, and a development strategy that includes translational CNS target-engagement biomarkers. Acurex is focused first on Essential Tremor, while building a broader T-type calcium channel franchise and maintaining a focused 15-LO neurodegeneration program.
strategy
Acurex is primarily pursuing a strategy to accelerate CU-00048 through the next key value-creating milestones in Essential Tremor, while selectively advancing additional T-type and 15-LO opportunities through collaborations, grants, and strategic partnerships.